Desmopressin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), PBAC (Australia) and SMC (Scotland) recommended or restricted desmopressin, while HAS (France) and PHARMAC (New Zealand) did not recommend it.
The file has been open for more than a decade: 19.5 years separate the first record, 4 Jan 2006 at HAS (France), from the most recent, 2025 at PBAC (Australia).
AOTMIT (Poland) changed its position: recommended on 12 May 2017, not recommended by 15 Nov 2018.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess desmopressin, on 4 Jan 2006; PBAC (Australia) did not open a file until 2025 — an unusually long tail of 19.5 years between the earliest and latest system to look at it.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed desmopressin to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales) and SMC (Scotland).
3 of the 6 agencies here assessed desmopressin more than once, PHARMAC (New Zealand) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for desmopressin.
The full ledger for desmopressin reads 3 not recommended, 2 recommended, 2 restricted and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Cranial diabetes insipidusPrimary nocturnal enuresis | Recommended | source |
| AOTMIT (Poland) | 15 Nov 2018 | Noqturina reimbursement recommendation | not recommended | source |
| AWMSG (Wales) | 17 Oct 2017 | Treatment of nocturia due to idiopathic nocturnal polyuria in adults | recommended with restrictions (full) | source |
| SMC (Scotland) | 7 Aug 2017 | symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. | accepted (restricted) | source |
| HAS (France) | 4 Jan 2006 | Listing (Transparency Committee) | ASMR V | source |
4 further decisions for desmopressin, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- carbetocin — same ATC class H01B — Pituitary and hypothalamic hormones
- pasireotide — also decided by AWMSG in 2017Q4
- 5-aminolaevulinic acid — also decided by AWMSG in 2017Q4
- bevacizumab — also decided by AWMSG in 2017Q4
- fluticasone / umeclidinium / vilanterol — also decided by AWMSG in 2017Q4
- burosumab — also decided by AWMSG in 2017Q4
Coverage: 9 decisions for desmopressin from 6 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class H01B — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.